Anavex Life Sciences
Market Cap
260M
Short interest (May 15)
20.8%
Net Short (Jun 03 ): 0.0%
Borrow Fee
0.72%
↓ 53.7%
Available Shares
900K
↓ 26.9%
Price Chart
Company Overview
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.